Table 7 Research design and methodology of scoping review TAND studies
Animal studies (n = 30) | Case studies (n = 47) | Cohort studies (n = 153) | |
|---|---|---|---|
Study designa | |||
Quantitative | 30 (100%) | 12 (26%) | 147 (96%) |
Qualitative | N/A | 45 (96%) | 13 (9%) |
Descriptive | 42 (89%) | ||
‘Typically qualitative’ | 3 (6%) | ||
Control group (e.g. typically developing) | N/A | N/A | 23 (15%) |
Contrast group (e.g. genetic syndrome) | N/A | N/A | 15 (10%) |
Multiple control and contrast groups | N/A | N/A | 5 (3%) |
Methodologya | |||
Medical record review | N/A | 41 (87%) | 67 (44%) |
Standardised questionnaires | N/A | 3 (6%) | 52 (34%) |
Interviews (standardised/clinical/research) | N/A | 0 (0%) | 38 (25%) |
Clinical report | N/A | 1 (2%) | 0 (0%) |
Neuroimaging | 23 (77%) | 42 (89%) | 74 (48%) |
Direct neuropsychological assessment | N/A | 12 (26%) | 33 (22%) |
IQ assessment | N/A | 17 (36%) | 80 (52%) |
Direct behavioural assessment | 28 (93%) | 27 (57%) | 9 (6%) |
Physiological examination | 14 (47%) | 39 (83%) | 35 (23%) |
Diagnostic assessment | N/A | 15 (32%) | 51 (33%) |
TAND Checklist | N/A | 1 (2%) | 6 (4%) |
Remote methodologya | |||
Online survey | N/A | 0 (0%) | 9 (6%) |
Telephone interview measures | N/A | 0 (0%) | 4 (3%) |
Mobile application | N/A | 0 (0%) | 0 (0%) |
Interventiona | |||
Non-pharmacological | 15 (50%) | 8 (17%) | 0 (0%) |
Pharmacological | 24 (80%) | 15 (32%) | 8 (5%) |
mTORi | 14 (47%) | 7 (15%) | 5 (3%) |
Other | 4 (13%) | 0 (0%) | 4 (3%) |